Given the importance and novelty of our AIDS cure research, the news of the publication of our pioneering pilot study exploring SupT1 cell infusion therapy for HIV in humanized mice has been reported by more than 230 international news outlets such as Yahoo! Finance, Reuters, Bloomberg, MarketWatch, Boston Globe, Seeking Alpha, Wichita Business Journal, Milwaukee Journal Sentinel, News9.com, Wall Street Online Germany, and Medical News Today among many others, resulting in the study ranking among the top 5% of all research outputs tracked by Altmetric.
About the project
Innovative Bioresearch Ltd is a privately held biotech company founded by Italian research scientist Jonathan Fior with the goal of bringing innovation to the field of HIV, cancer and regeneration research. The INNBC and INNBCL crypto assets were issued to expand ourbiomedical research, as well as to provide a direct utility as a means of payment to access on one hand all our medical products and services, and on the other to become the most widely used digital payment system used by a wide number of companies and commercial activities. We are also working on the development of a novel DApp for decentralizing scientific data.
INNBC AND INNBCL
INNBC, InnovativeBioresearchCoin (0xB67718b98d52318240c52E71A898335da4A28c42) is the original and main token issued by Innovative Bioresearch for developing our novel AIDS cure research. INNBCL, InnovativeBioresearchClassic (0x8cc3e2bdc17682c622eb789eda23fbd6988c84da) is a sister coin we issued at a later time for further supporting our research so we could also start cancer/regeneration research projects. Holding INNBCL makes you elegible for INNBC airdrop and bonuses, just like when we recently listed INNBC on top exchange BigOne, and INNBCL token holders were rewarded by INNBC bonuses.
INNBC AND INNBCL tokens are both accepted as a means of payment to access our pharmaceutical/medical products and services. However, INNBC is the main token accepted as a means of payment by our commercial partners. For example, we launched a partnership with the French electronic giant ARCHOS, where vouchers are given at discount for purchases to INNBC token holders. As a next step to improve mass adoption of INNBC, we launched an INNBC Ebay store where a great variety of products, starting from electronic products first, are available for purchase directly with INNBC tokens at discounted price with respect to EUR.
We believe that providing such a straightforward utility (i.e., you can directly use our Token to access actual physical goods and services as you would with a fiat currency) can seriously help reaching those customers who are not normally into the crypto world.
We also launched a partnership program with some UK based JDM IMPORTERS for accessing a selection of high quality JDM classic cars using our crypto to get discounts. Here at Innovative Bioresearch we love JDM cars. Because, let’s face it; imports will always beat muscle cars. Amazingly, we were able to attract the attention of our beloved car manufacturer Nissan, who featured our CEO for advertising their supercar Nissan GTR on their official social channels. A partnership with Nissan is therefore in the work, stay tuned for upcoming news!
INNBC DEFI PRODUCTS
We are always the first to lead innovation in crypto. Not only we launched an Ebay store where you can use INNBC to buy electronic items, not only INNBC is the only real biotech token developing novel and very valuable biomedical research for HIV, cancer and COVID but we also are launching some phenomenal #defi products:
1)"EARN". The first #defi product will allow you to earn stacking bonuses that instead of being issued in INNBC will be issued in USDT. The bonus rate will start from 6% annual rates for holding 500$ woth of INNBC up to 20% for holding over $2000 worth of INNBC. Bonuses will be distributed every 6 months during a 12 month old holding cycle.
If there is high demand, we will also discuss the option to offer bonuses starting from lower holdings than 500$ worth INNBC as a starting point.
2)"SECURE". The second #INNBC #defi product will be limited to a closed number of users who commit to a monthly purchase and will hold their tokens for longer periods. We will offer a price protection mechanism where more tokens are issued to your wallet in the event that price goes down, so your balance will stay the same. When the price goes up you will have the option to sell 5% of your holdings through our smart bot that can sell the tokens without causing price dump.
With this option you can have peace of mind with respect to your holdings as we will take care of ensuring your balance stays intact regardless of market price, and when market goes up you can also take advantage of our smart bot to eventually liquidate 5% of your holdings to cash out without causing price dump on the market.
We believe our defi products are one of the best offers in the current market and add substantial value to INNBC!
The Limitations of Current Centralized Databases for Clinical Data
Traditionally, all data generated by scientific research is collected in the form of a scientific article, which is published in a peer reviewed scientific journal, and it is usually made available on a public database such as the NIH’s pubmed database (https://www.ncbi.nlm.nih.gov/pubmed). When a novel therapeutic strategy, such as our novel cell-based therapy for HIV, SupT1 cell infusion therapy, goes through the several stages of clinical research, different research teams all over the world may perform the research. And once the therapy is finally approved for human treatment, different clinicians all over the world may administer the treatment to patients. This means that when a research team wants to perform clinical research, they have to go through the tedious and time consuming process of searching for all the published data from previous trials, read all the papers, select the useful data, and make the best possible interpretation of the data to create a protocol for their trial, personalizing it for their typology of patients. In fact, every patient may have different individual characteristics (e.g., age, ethnicity, HIV tropism) and thus may require personalized treatment protocols. And the same issue is present when clinicians begin to administer an approved treatment to patients; they have to go through all the papers and make a best guess on what treatment protocol should be used. As mentioned, this process of accessing clinical data can be quite tedious and time consuming, but it can also introduce human error.
A Possible Solution: A Decentralized Database Using the Blockchain to Store and Access Clinical Data
A possible solution to the challenge posed by having to access clinical data from the current ancient system could be provided by the creation of a decentralized database for clinical data using the blockchain technology. This is what we are proposing with the creation of the “You’re not alone” DApp. First, let’s focus on the blockchain aspect of the app, we will explain why it has such a name later. The “You’re not alone” app would feature a user-friendly interface allowing any clinician running a clinical investigation to enter the data produced by their trials. The application would allow the input of a broad range of individual parameters for each treated patient, such as age, ethnicity, disease progression stage, viral tropism of HIV virus carried, along with the clinical protocol used (e.g., dosage of SupT1 cells infused each week) and the outcome of the treatment (e.g., viral load, CD4+ T cell count). The app would then access and elaborate the data on the fly; statistical analysis (means, standard deviations, correlations, power) and even the elaboration of suggested treatment profiles that could work best for each type of patient could be performed. This would take away the burden of having to manually search and process all the data as in the current centralized databases. And such an application would have an infinite potential for growing. For instance, an amazing feature could be to store in the database the genotypic information of the HIV virus carried by each patient, allowing to keep track of all mutations and genetic modifications caused by the treatment as well as the resulting viral phenotypic changes. Therefore, such a database would be constantly growing and evolving as new parameters are added to it, and it would be always available, anytime, anywhere, and to anyone connected. Such an app would help speed up tremendously the clinical development stages of our AIDS cure research; it could be a game changer.
Now, let’s explain why we named the application “You’re not alone”. The application will also document the progress of our AIDS cure research project, featuring periodic updates such as articles, vlogs. This will create a community where HIV seropositive people can stay up to the date, comment, share, interact with us working on the cure, and with each others. Something that creates a bridge between HIV seropositive people and us research scientists working on the cure. Something that allows the HIV seropositive community and anyone interested to be part of this journey. Something that can send the message that they are not alone in their battle. That we are fighting for them. That we care about them. A message of hope. Our vision and intention is therefore to create an application that will also act as a social app for HIV seropositive people to participate and create new topics and discussions to support each others and stand together in the fight against AIDS. Discussions will be moderated by a team of moderators, and qualified physicians will also participate in the community for providing expert medical advice as a free service to the users. The application will also provide information about all the ongoing clinical trials, how to participate, and once the treatment is approved, it will provide information about the clinics and hospitals offering the treatment, and how to make appointments with legit clinicians that are officially collaborating with us.
We are developing the "You're not alone" application specifically for our research, to overcome the limitations of current centralized databases. However, we believe there may be interest in using our application by other research organizations. After all, this would be an application designed by a research scientist for research scientists. Our database will be open to any company or institution interested in using our app for storing their clinical data. Moreover, we will encourage them to do so as we believe that scientific data should be shared publicly.
All altcoins are scam. What can you say about it?
Altcoins are a very valuable tool for our society, but you have to carefully check that the project is legit before investing. We can tell you this about our project. We are a biotech company performing novel biomedical research, and scientific research is something serious. One of the things that sets the project apart from the other coins is that it is based on our AIDS cure research. Behind our project there are therefore many years of hard work and investments to perform and publish our research. Investors with us know that they are investing into something real and concrete, and not in one of those bubble soap projects that disappear the day after the ICO because they are not solving any real issue and are just a collection of fancy presentations. With us, investors can easily verify that our project is something real and legit by checking the publications on the NIH database pubmed.
Fior J. An Initial In Vitro Investigation into the Potential Therapeutic Use of SupT1 Cells to Prevent AIDS in HIV-Seropositive Individuals. PLoS ONE. 2012;7(5):e37511. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22701517
Fior J. Is a pacific coexistence between virus and host the unexploited path that may lead to an HIV functional cure? Viruses. 2013;5(2):753-7. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23430684
Fior J. Salamander regeneration as a model for developing novel regenerative and anticancer therapies. J Cancer. 2014;5(8):715-9. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/25258653
Fior J. SupT1 Cell Infusion as a Possible Cell-Based Therapy for HIV: Results from a Pilot Study in Hu-PBMC BRGS Mice. Vaccines. 2016;4(2):13. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/27128948
Moreover, we are working on solving a real global issue such as developing a low cost cure solution for AIDS. There were 36.7million people infected by HIV globally in 2016, 17.5million of which were left untreated, according to UNAIDS. Our mission is to develop a low cost cell-based therapy solution for HIV to allow access to the treatment for those individuals who are normally left untreated due to social and/or economic limitations.
The term JDM stands for "Japanese domestic market" and refers to Japan's home market for vehicles. We partnered with a series of top class JDM importers to offer discounts opportunity to spend INNBC\L to buying wonderful JDM supercars such as Skylines and Supras as wel as cars parts. And this is just one prestigious commercial partnership allowing to use INNBC\L for actual physical goods. Another amazing commercial partnership is with the French electronic giant Archos, allowing a 20% discounts on their hardware wallets for INNBC\L token holders (the full text of the press release announcing the partnership can be found here: https://www.archos.com/corporate/press/press_releases/EN_PR_ARCHOS_Innovative_Bioresearch_20180709.pdf). More are coming. But why JDM classics for a biomedical research related project, other than because they are simply awesome? The car enthusiast community is one of the most welcoming and sensitive community when it comes to supporting social issues such as fighting AIDS. Therefore, we believe that having INNBC\L spendable for classic iconic JDM cars is true to the spirit of this project, which is to solve a serious global health problem. In addition, the automotive industry is something very responsive and therefore we believe in additional future productive partnerships for further expanding our Token economy, making it constantly growing and successful. We also believe that providing such a straightforward utility (i.e., you can directly use our Token for physical goods as you would with a fiat currency) can seriously help reaching those customers who are not normally into the crypto world.
What exactly will I own after Token purchase? A company’s share?
The INNBC\L Token is a utility Token and not an equity Token, so it does not represent a company’s share. Nonetheless, it will be tradable on exchanges. It will also be spendable for all our future medical treatments and services, along with physical goods from conventioned partners.
Do the Tokens comply with ERC20 standard? Can I transfer them to a third-party ETH wallet?
Yes. The token is totally compliant with the ERC20 standard of the Etherum blockchain.
Where can I buy INNBC\L? Where is the token listed? .
INNBCL has been listed on Coinmarketcap, where you can check all available markets. INNBC will soon be added to cmc as well (it is listed on Mercatox exchange).
What value your tokens will bring for me as an investor?
First, you will be able to spend INNBC\L for accessing all our future medical treatments/products/services, meaning that the is backed by the value of our biomedical research. In addition, it will also be spendable to buy goods and services from selected partners. Furthermore, we are woking on the development of the "You're not alone" app, where INNBC Tokens will be spendable to access privileged features, such as access to moderation roles allowing to earn from in app ads.
I've never heard about your company. Who are you? Are there any references to you in media?
We are a privately held biotech company based in Italy. Owned and founded by research scientist Jonathan Fior with the goal of bringing innovation to the field, with a focus on HIV, cancer and regeneration research. Given the importance and novelty of our AIDS cure research, the news of the publication of our latest study exploring SupT1 cell infusion therapy for HIV in humanized mice has been reported by more than 230 international news outlets such as Yahoo! Finance, Reuters, Bloomberg, MarketWatch, Boston Globe, Seeking Alpha, Wichita Business Journal, Milwaukee Journal Sentinel, News9.com, Wall Street Online Germany, and Medical News Today among many others, resulting in the study ranking among the top 5% of all research outputs tracked by Altmetric.
The press release announcing our ICO was also widely mentioned by the media. Being mentioned on PRnewswire and Yahoo Finance is a badge of trust for a company, which is crucial during a token sale to distinguish legit projects from scamcoins.
In what jurisdiction is your business located?
Italy and United Kingdom.
Do you have analogues or competitors?
Actually, we have no competitors working with a similar blockchain project related to AIDS cure research, and offering a Token backed by the value of actual physical goods is also something very distinctive.
What will happen if your project will close?
Hopefully, it won't. We are very committed at making this project a success as we devoted our lives to the mission of developing a cure for AIDS. In addition, we hope that being able to use our INNBC Token to buy actual physical goods such as wonderful JDM cars will also help making it successful.
Why exactly do you need blockchain technology for the purpose of storing clinical data? Couldn't you just build a well secured database that is fast to search in using a traditional centralized platform?
There are several good reasons actually.
•Immutability. Scientific data need to be immutable. Once a study is peer reviewed and published, its data must be permanently stored and never altered. In the blockchain, all data is stored in every single node, never ceasing to exist, and always staying on the blockchain. It is immutability that gives the blockchain its openness and BFT (Byzantine Fault Tolerance).
•Decentralization. The blockchain is designed to be distributed and synchronized across networks, making data freely available to anyone. We believe that scientific data should be shared and not being hidden behind a firewall.
•Security. The kind of transactions that can be performed are strictly defined in advance and stored in the blockchain as “smart contracts”; this prevents fraudulent data from being added to the blockchain thus ensuring integrity of the database. By contrast, it would be much easier to compromise a centralized database.
In conclusion, although it is true that such an application could be implemented with a centralized system, decentralization is the only way to ensure the data is not manipulated, and all information is publicly available in a platform that can't be influenced by the will of any particular entity or government. Decentralization is essential to hand over administrative authority from central institutions managing the data, such as governments and private entities, to the collectivity. In fact, if the database is controlled by one single entity, being it a private entity or government, it means that such entity has total control over the database, and such control can be influenced by personal conflicts of interests. Therefore, decentralization is the only way to ensure that scientific data become public property. In addition, in terms of costs, creating an infrastructure ensuring the same level of data integrity protection of a smart contract deployed on the Etherum blockchain, which is basically impossible to compromise, and most importantly, maintaining such a platform up and running, would simply not be feasible.